RhinAV_Evaluation of Treatments for Acute Viral Rhinitis, Rhinosinusitis, and Rhinopharyngitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorUniversity Hospital, Clermont-Ferrand
About this trial
The objective of this study is to conduct post-marketing clinical follow-up of four products: NS, NHE, NHG, and PIR. This follow-up will consist of collecting clinical data in real-life conditions to confirm the tolerance, safety, and efficacy of medical devices used in the treatment of acute viral rhinitis, rhinosinusitis, and rhinopharyngitis, while also assessing the benefit/risk ratio of the products.
Eligibility criteria
Qualifiers
Acute viral rhinitis or acute rhinosinusitis or viral rhinopharyngitis (sneezing, rhinorrhea, nasal obstruction, cough secondary to posterior rhinorrhea, sore throat) that began less than 72 hours prior to the inclusion visit, in the investigator's judgment,
Effective contraception for female patients of childbearing age.
Cooperation and sufficient understanding to comply with the requirements of the trial.
Acceptance of registration in the SI-RIPH VRB file.
Disqualifiers
Hypersensitivity/history of allergy to any of the product's components,
Complicated rhinitis, rhinosinusitis, or rhinopharyngitis (acute bacterial sinusitis, acute otitis media, acute bronchitis, or pneumonia) or severe cough that is poorly tolerated,
Chronic rhinosinusitis,
Allergic rhinosinusitis,
Trial design
Treatments tested in this trial
- PIR
- NS
- NHE
- NHG
Treatment groups
150 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov